Payment overview · 2025
General Payments
$73.83
4 reported records · 3 companies
Healthcare provider profile · identity verified
James T. Rogers, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SPRINGFIELD, MO · NPI 1346306115
Verified facts
What the public records show
CMS Open Payments records show James T. Rogers, MD received $73.83 in general payments during 2025 across 4 reported records.
PFIZER INC. accounted for 45.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.56 | 45.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.02 | 31.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.25 | 23.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $73.83 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $23.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 16 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 33 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 558 | 161 |
| Atorvastatin Calcium | Atorvastatin Calcium | 427 | 139 |
| Alprazolam | Alprazolam | 330 | 90 |
| Amlodipine Besylate | Amlodipine Besylate | 283 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 81 |
| Omeprazole | Omeprazole | 274 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 240 | 75 |
| Lisinopril | Lisinopril | 239 | 80 |
| Tramadol Hcl | Tramadol Hcl | 239 | 70 |
| Furosemide | Furosemide | 226 | 51 |
| Metformin Hcl | Metformin Hcl | 212 | 61 |
| Gabapentin | Gabapentin | 188 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 175 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 48 |
| Trazodone Hcl | Trazodone Hcl | 151 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 38 |
| Losartan Potassium | Losartan Potassium | 129 | 38 |
| Meloxicam | Meloxicam | 126 | 42 |
| Montelukast Sodium | Montelukast Sodium | 124 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 40 |
| Zolpidem Tartrate | Zolpidem Tartrate | 118 | 35 |
| Potassium Chloride | Potassium Chloride | 108 | 33 |
| Eliquis | Apixaban | 105 | 25 |
| Allopurinol | Allopurinol | 104 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 25 |
| Bupropion Hcl Sr | Bupropion Hcl | 86 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 30 |
| Carvedilol | Carvedilol | 82 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 23 |
| Glimepiride | Glimepiride | 81 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 79 | 23 |
| Celecoxib | Celecoxib | 74 | 13 |
| Pentoxifylline | Pentoxifylline | 73 | 14 |
| Sertraline Hcl | Sertraline Hcl | 71 | 16 |
| Finasteride | Finasteride | 70 | 17 |
| Synthroid | Levothyroxine Sodium | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 24 |
| Simvastatin | Simvastatin | 66 | 20 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 25 |
| Methylprednisolone | Methylprednisolone | 62 | 55 |
| Warfarin Sodium | Warfarin Sodium | 62 | 14 |
| Famotidine | Famotidine | 61 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 14 |
| Spironolactone | Spironolactone | 57 | 15 |
| Atenolol | Atenolol | 54 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 20 |
| Bupropion Xl | Bupropion Hcl | 51 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 49 | 13 |
| Diazepam | Diazepam | 46 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 46 | 17 |
| Indapamide | Indapamide | 46 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Irbesartan | Irbesartan | 45 | 17 |
| Jardiance | Empagliflozin | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Baclofen | Baclofen | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 37 | 11 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Ozempic | Semaglutide | 33 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 32 | suppressed |
| Nitroglycerin | Nitroglycerin | 32 | 18 |
| Lorazepam | Lorazepam | 30 | 17 |
| Pregabalin | Pregabalin | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | 11 |
| Estradiol | Estradiol | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 21 |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 17 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Prednisone | Prednisone | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Amiloride Hcl | Amiloride Hcl | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $73.83 · 4 records | PFIZER INC. | ABRYSVO, BEXSERO, COMIRNATY, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, ZAVZPRET | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error